Clinical Trial: A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06964113) titled 'A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice' on May 02.

Brief Summary: The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Ulcerative Colitis

Intervention: DRUG: Filgotinib Maleate

Administered as oral tablets.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eisai Korea Inc.

Disclaimer: Curated by HT Syndication....